2 completed. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow CMAB009: new trials by email Literature Review of CMAB009 trials Research Report on CMAB009
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer CMAB009, Irinotecan, Folinic acid - Metastatic Colorectal Cancer | Phase 3 | Completed | Taizhou Mabtech Pharmaceutical Co.,Ltd | 520 | 2017-12-12 | 2025-05-23 |
| Study of CMAB009 to Treat KRAS Wild Type Metastatic Colorectal Cancer CMAB009 plus Irinotecan, Irinotecan-only and sequential-CMAB009 - Metastatic Colorectal Cancer | Phase 2 / Phase 3 | Completed | Shanghai Zhangjiang Biotechnology Limited Company | 512 | 2009-05-31 | 2019-04-10 |
Shanghai Zhangjiang Biotechnology Limited Company (1) · Taizhou Mabtech Pharmaceutical Co.,Ltd (1)
China (1)
B C Mei (1) · B Feng (1) · B Li (1) · B Yi (1) · C Hong (1) · C Y Gui (1) · C Ying (1) · D W Chao (1) · F J Feng (1) · F Min (1) · H C Hong (1) · H X Hua (1) · J Bin (1) · L H Jie (1) · L Jin (1)